Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7402913 | 0.98 | ALDH1A1 (0.48) | ALDH1A1CES2BCHECES1MCL1 | |
| SCHEMBL113314 | 0.76 | GSK3B (0.40) | ALDH1A1CES2BCHECES1MEN1 | |
| SCHEMBL29394879 | 0.76 | GSK3B (0.40) | ALDH1A1CES2BCHECES1MEN1 | |
| SCHEMBL11397543 | 0.76 | ALDH1A1 (0.40) | ALDH1A1CES2BCHECES1MCL1 | |
| Hydrochloric Acid SCHEMBL20475155 | 0.74 | GSK3B (0.39) | ALDH1A1CES2BCHECES1MEN1 | |
| SCHEMBL8581486 | 0.72 | MEN1 (0.45) | ALDH1A1CES2BCHECES1MEN1 | |
| SCHEMBL30613413 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CES2BCHECES1MCL1 | |
| SCHEMBL1266199 | 0.72 | ALDH1A1 (0.61) | ALDH1A1CES2BCHECES1MCL1 | |
| SCHEMBL29473502 | 0.70 | GRK6 (0.45) | ALDH1A1MCL1KMT2AMAPTCYP3A4 | |
| SCHEMBL2637178 | 0.70 | GRK6 (0.45) | ALDH1A1MCL1KMT2AMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0430190-B1 | New tricyclic compounds | SYNTEX INC (US) | 1995-07-05 | — | — | EP | claimed |
| US-20250186342-A1 | ANTIEMETIC COMBINATIONS | SPES PHARMACEUTICALS INC. | 2025-06-12 | — | — | US | disclosed |
| US-20240415848-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-19 | — | — | US | disclosed |
| US-20120122915-A1 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | ROSSETTO PIERLUIGI (IT) | 2012-05-17 | — | — | US | disclosed |
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HELSINN HEALTHCARE SA (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-1596862-B1 | USE OF PALONOSETRON FOR TREATING POST-OPERATIVE NAUSEA AND VOMITING | HELSINN HEALTHCARE SA (CH) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258367-A2 | Use of palonosetron for treating post-operative nausea and vomiting | Helsinn Healthcare S.A. (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-7737280-B2 | Processes for preparing palonosetron salts | SICOR INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2155199-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | Chemagis Ltd. (IL) | 2010-02-24 | — | — | EP | disclosed |
| US-20100016593-A1 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | SICOR INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2008146283-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2008-12-04 | — | — | WO | disclosed |
| EP-1966197-A2 | PROCESSES FOR PREPARING PALONOSETRON SALTS | Sicor, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1960397-A2 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | Sicor Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080200681-A1 | Processes for preparing palonosetron salts | SICOR INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008051564-A2 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | SICOR INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051539-A2 | PROCESSES FOR PREPARING PALONOSETRON SALTS | SICOR INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20060079545-A1 | Palonosetron for the treatment of chemotherapy induced emeses | HELSINN HEALTHCARE SA (CH) | 2006-04-13 | — | — | US | disclosed |
| US-20060074101-A1 | Method of treating post operative nausea and vomiting | HELSINN HEALTHCARE SA (CH) | 2006-04-06 | — | — | US | disclosed |
| EP-0457243-A1 | Novel tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| US-4959361-A | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists | HOFFMANN-LA ROCHE INC. (US) | 1990-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186342-A1 | ANTIEMETIC COMBINATIONS | CRH, AVPR2, AVPR1B | ALDH1A1 3109/4885CES2 1545/4885BCHE 1207/4885 |
| US-20120122915-A1 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | HTR5A, HTR3A, LPXN | ALDH1A1 4651/4885CES2 3913/4885BCHE 2104/4885 |
| US-20240415848-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | ALDH1A1 1624/4885CES2 785/4885BCHE 268/4885 |
| US-20100016593-A1 | CRYSTALLINE FORMS OF PALONOSETRON HYDROCHLORIDE | HTR5A, HTR3A, LPXN | ALDH1A1 4651/4885CES2 3913/4885BCHE 2104/4885 |
| US-20080200681-A1 | Processes for preparing palonosetron salts | CYP3A43, CYP3A5, CYP4A11 | ALDH1A1 3939/4885CES2 2998/4885BCHE 2754/4885 |
| US-20060079545-A1 | Palonosetron for the treatment of chemotherapy induced emeses | HTR3A, HTR3C, HTR3B | ALDH1A1 4262/4885CES2 1632/4885BCHE 1064/4885 |
| US-20060074101-A1 | Method of treating post operative nausea and vomiting | HTR3A, HTR3C, HTR5A | ALDH1A1 3930/4885CES2 1392/4885BCHE 267/4885 |
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HTR3A, HTR3C, HTR3B | ALDH1A1 4262/4885CES2 1632/4885BCHE 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.